Cartherics

Cartherics is a biotechnology company developing immune cell therapies for cancer and other diseases. Its lead product, CTH-401, is a natural killer (NK) cell therapy targeting ovarian cancer, currently in pre-clinical stages. The company's platform uses iPSCs generated from donated cord blood to create allogeneic cell therapies.

Buy Funded Startups lists

Funding Round: Private Financing

Funding Amount: AUD$15M

Date: 30-Sep-2024

Investors:

Markets: Biotechnology, Cell Therapy, Immunotherapy, Oncology

HQ: Notting Hill, Victoria, Australia

Founded: 2014

Website: https://cartherics.com/

LinkedIn: https://www.linkedin.com/company/cartherics-pty-ltd

Twitter: https://twitter.com/cartherics

Instagram: